Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.58
-0.03 (-0.53%)
Mar 12, 2025, 1:55 PM EST - Market open
Solid Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | - | 8.09 | 13.62 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | -40.57% | - | - | Upgrade
|
| Cost of Revenue | 96.43 | 76.56 | 78.42 | 58.74 | - | Upgrade
|
| Gross Profit | -96.43 | -76.56 | -70.33 | -45.12 | - | Upgrade
|
| Selling, General & Admin | 33.3 | 27.75 | 24.08 | 27.14 | 21.58 | Upgrade
|
| Research & Development | - | - | - | - | 64.88 | Upgrade
|
| Operating Expenses | 33.3 | 27.75 | 24.08 | 27.14 | 86.46 | Upgrade
|
| Operating Income | -129.73 | -104.32 | -94.4 | -72.25 | -86.46 | Upgrade
|
| Interest Expense | -0.34 | -0.44 | - | - | - | Upgrade
|
| Interest & Investment Income | 9.47 | 7.58 | 2.62 | 0.06 | 0.12 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.1 | 1.1 | -0.38 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -124.7 | -96.08 | -92.17 | -72.19 | -86.35 | Upgrade
|
| Merger & Restructuring Charges | - | 0.06 | -12.05 | - | -1.94 | Upgrade
|
| Other Unusual Items | - | - | 18.24 | - | - | Upgrade
|
| Pretax Income | -124.7 | -96.02 | -85.98 | -72.19 | -88.29 | Upgrade
|
| Earnings From Continuing Operations | -124.7 | -96.02 | -85.98 | -72.19 | -88.29 | Upgrade
|
| Net Income | -124.7 | -96.02 | -85.98 | -72.19 | -88.29 | Upgrade
|
| Net Income to Common | -124.7 | -96.02 | -85.98 | -72.19 | -88.29 | Upgrade
|
| Shares Outstanding (Basic) | 41 | 20 | 9 | 7 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 20 | 9 | 7 | 3 | Upgrade
|
| Shares Change (YoY) | 105.27% | 133.60% | 19.58% | 105.58% | 28.91% | Upgrade
|
| EPS (Basic) | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | Upgrade
|
| EPS (Diluted) | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | Upgrade
|
| Free Cash Flow | -100.67 | -95.7 | -100.99 | -79.05 | -57.5 | Upgrade
|
| Free Cash Flow Per Share | -2.47 | -4.81 | -11.86 | -11.10 | -16.61 | Upgrade
|
| Operating Margin | - | - | -1166.35% | -530.50% | - | Upgrade
|
| Profit Margin | - | - | -1062.28% | -530.01% | - | Upgrade
|
| Free Cash Flow Margin | - | - | -1247.74% | -580.36% | - | Upgrade
|
| EBITDA | -127.27 | -101.73 | -92 | -69.29 | -82.54 | Upgrade
|
| D&A For EBITDA | 2.46 | 2.58 | 2.41 | 2.96 | 3.92 | Upgrade
|
| EBIT | -129.73 | -104.32 | -94.4 | -72.25 | -86.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.